Terms: = Lung cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Prognosis
1197 results:
1. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
2. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
3. The Evaluation and Management of lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era.
Trovarelli G; Rizzo A; Cerchiaro M; Pala E; Angelini A; Ruggieri P
Curr Oncol; 2024 Apr; 31(4):2158-2171. PubMed ID: 38668063
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract] [Full Text] [Related]
5. Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China.
Liu W; Zhou D; Zhang L; Huang M; Quan R; Xia R; Ye Y; Zhang G; Shen Z;
J Cancer Res Clin Oncol; 2024 Apr; 150(4):205. PubMed ID: 38642154
[TBL] [Abstract] [Full Text] [Related]
6. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
Nishimura T; Fujimoto H; Fujiwara T; Ito K; Fujiwara A; Yuda H; Itani H; Naito M; Kodama S; Furuhashi K; Yagi A; Saiki H; Yasuma T; Okano T; Tomaru A; Tanigawa M; Yoshida M; Hataji O; Ibata H; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
Cancer Med; 2024 Apr; 13(8):e7188. PubMed ID: 38629295
[TBL] [Abstract] [Full Text] [Related]
7. The characteristics and prognosis of different disease patterns of multiple primary lung cancers categorized according to the 8th edition lung cancer staging system.
Wang Y; Fang L; Hu X; Wu H; Zhou L; Xue Q; Gao S; He J
J Cardiothorac Surg; 2024 Apr; 19(1):200. PubMed ID: 38600565
[TBL] [Abstract] [Full Text] [Related]
8. Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control study.
Mei C; Wang T; Xu B; Wu S; Zhang X; Lv Y; Zhang Y; Liu Z; Gong W
BMC Pulm Med; 2024 Apr; 24(1):167. PubMed ID: 38589850
[TBL] [Abstract] [Full Text] [Related]
9. Clinical outcomes of interstitial lung abnormalities: a systematic review and meta-analysis.
Seok J; Park S; Yoon EC; Yoon HY
Sci Rep; 2024 Mar; 14(1):7330. PubMed ID: 38538680
[TBL] [Abstract] [Full Text] [Related]
10. prognosis and prognostic factors of lung cancer complications in patients with rheumatoid arthritis.
Fujita S; Nakano K; Nagasu A; Hiramatsu-Asano S; Akagi T; Morita Y
Int J Rheum Dis; 2024 Mar; 27(3):e15069. PubMed ID: 38514918
[TBL] [Abstract] [Full Text] [Related]
11. From pixels to prognosis: unveiling radiomics models with SHAP and LIME for enhanced interpretability.
Raptis S; Ilioudis C; Theodorou K
Biomed Phys Eng Express; 2024 Mar; 10(3):. PubMed ID: 38498925
[TBL] [Abstract] [Full Text] [Related]
12. Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
Lin Y; Cao Q; Hong A; Liang X
Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
[TBL] [Abstract] [Full Text] [Related]
13. lung cancer outcomes in the elderly: potential disparity in screening.
Singh A; Mazzola E; Xie Y; Marshall MB; Jaklitsch MT; Wilder FG
Eur J Cardiothorac Surg; 2024 Mar; 65(3):. PubMed ID: 38445715
[TBL] [Abstract] [Full Text] [Related]
14. MECOM: a bioinformatics and experimentally identified marker for the diagnosis and prognosis of lung adenocarcinoma.
Li A; Li M; Wang J; Zhou J; Yang T; Fan M; Zhang K; Gao H; Ren H; Chen M
Biomark Med; 2024 Jan; 18(2):79-91. PubMed ID: 38440890
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Behavioral Health Disorders on Surgical Outcomes in cancer Patients.
Katayama ES; Woldesenbet S; Munir MM; Endo Y; Rawicz-Pruszyński K; Khan MMM; Tsilimigras D; Dillhoff M; Cloyd J; Pawlik TM
J Am Coll Surg; 2024 Apr; 238(4):625-633. PubMed ID: 38420963
[TBL] [Abstract] [Full Text] [Related]
16. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
[TBL] [Abstract] [Full Text] [Related]
17. Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer.
Khan C; Rusan NM
Trends Cancer; 2024 Apr; 10(4):289-311. PubMed ID: 38350736
[TBL] [Abstract] [Full Text] [Related]
18. Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
Averbuch I; Tschernichovsky R; Yust-Katz S; Rotem O; Limon D; Kurman N; Icht O; Reinhorn D; Moskovitz M; Hanovich E; Benouaich-Amiel A; Siegal T; Zer A; Gal O
J Neurooncol; 2024 Feb; 166(3):461-469. PubMed ID: 38324192
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
Zhang Y; Li Z; Huang Y; Zou B; Xu Y
BMJ Open; 2024 Jan; 14(1):e073887. PubMed ID: 38296306
[TBL] [Abstract] [Full Text] [Related]
20. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract] [Full Text] [Related]
[Next]
